Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMERICAN DENTAL LASER WILL MARKET INCISIVE TECHNOLOGIES, INC.'S PULSE MASTER

This article was originally published in The Gray Sheet

Executive Summary

AMERICAN DENTAL LASER WILL MARKET INCISIVE TECHNOLOGIES, INC.'S PULSE MASTER dental laser as part of a planned joint venture between the two firms announced Feb. 12. The Pulse Master, a 10-watt Nd:YAG pulse laser with adjustable pace settings from 10 to 100 pulses per second, was cleared by FDA in December for soft tissue applications, according to ADL. ADL's marketing of the Pulse Master will be the first initiative of the joint venture, which will involve development, production and marketing of dental lasers, ADL says. Under the arrangement, Incisive will be responsible for research and development, manufacturing and service, while ADL will be responsible for sales and distribution. The announcement of the joint venture plan comes one week after the settlement of a dispute between ADL and Sunrise Technologies related to a manufacturing and marketing pact ("The Gray Sheet" Feb. 8, In Brief). In April, the companies sought arbitration of the dispute over contracts under which Sunrise manufactured the dLase 300 three-watt for ADL ("The Gray Sheet" April 27, I&W-1). The settlement terminated Sunrise's exclusive rights to manufacture lasers for ADL and affirmed ADL's ownership of dental laser patents. Under the settlement, Sunrise also obtained a license to use ADL's dental patents and agreed to supply ADL with the dLase 300 three-watt dental laser worldwide and an eight-watt dental laser in the U.S. and Japan until Feb. 1994. ADL currently does not offer the eight-watt device and has not determined whether it will be added to its product line. If ADL chooses to find another manufacturing partner after Sunrise's obligation runs out, Incisive would be a likely candidate. ADL recently expanded its dental product offerings with the launch of its KCP 2000 kinetic cavity preparation device. Positioned as an alternative to dental drills, the KCP 2000 sprays tiny particles of alpha alumina, a form of aluminum oxide, on teeth to remove decay, enamel or tooth structure. According to ADL, the device does not cause vibration and eliminates the need for anesthesia in 90% of cavity patients and the need for acid etching in placement of white colored fillings. Corpus Christi-based Texas Airsonics manufactures the device for ADL under an OEM agreement. ADL owns all patents and distribution rights to the device, which is selling for about $25,000.

You may also be interested in...



US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation

CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach. 

New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments

Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel